143 related articles for article (PubMed ID: 34397208)
1. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
Fournier JCL; Evans JP; Zappacosta F; Thomas DA; Patel VK; White GV; Campos S; Tomkinson NCO
ACS Chem Biol; 2021 Sep; 16(9):1644-1653. PubMed ID: 34397208
[TBL] [Abstract][Full Text] [Related]
2. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.
Liu X; Feng D; Zheng M; Cui Y; Zhong D
Drug Metab Pharmacokinet; 2020 Oct; 35(5):456-465. PubMed ID: 32847720
[TBL] [Abstract][Full Text] [Related]
3. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
6. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
7. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
[TBL] [Abstract][Full Text] [Related]
9. Discovery of (
Li F; Liang X; Jiang Z; Wang A; Wang J; Chen C; Wang W; Zou F; Qi Z; Liu Q; Hu Z; Cao J; Wu H; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2020 Nov; 63(22):13973-13993. PubMed ID: 33180507
[TBL] [Abstract][Full Text] [Related]
10. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Investigation of Lysine-Targeted Covalent Inhibition of PI3Kδ via ONIOM QM:QM Computations.
Fındık V; Varınca Gerçik BT; Sinek Ö; Erdem SS; Ruiz-López MF
J Chem Inf Model; 2022 Dec; 62(24):6775-6787. PubMed ID: 35980989
[TBL] [Abstract][Full Text] [Related]
12. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
[TBL] [Abstract][Full Text] [Related]
14. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
Perry MWD; Abdulai R; Mogemark M; Petersen J; Thomas MJ; Valastro B; Westin Eriksson A
J Med Chem; 2019 May; 62(10):4783-4814. PubMed ID: 30582813
[TBL] [Abstract][Full Text] [Related]
15. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
[TBL] [Abstract][Full Text] [Related]
16. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
17. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
20. Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development.
Tang G; Wang W; Zhu C; Huang H; Chen P; Wang X; Xu M; Sun J; Zhang CJ; Xiao Q; Gao L; Zhang ZM; Yao SQ
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202316394. PubMed ID: 38248139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
